Assuntos
Tecnologia Disruptiva/legislação & jurisprudência , Sistemas de Liberação de Medicamentos/métodos , Desenvolvimento de Medicamentos/métodos , Indústria Farmacêutica/legislação & jurisprudência , Produtos Biológicos/uso terapêutico , Terapia Baseada em Transplante de Células e Tecidos/estatística & dados numéricos , Lentes de Contato , Aprovação de Drogas/legislação & jurisprudência , Medicamentos Genéricos , Equipamentos e Provisões/estatística & dados numéricos , Terapia Genética/legislação & jurisprudência , Terapia Genética/estatística & dados numéricos , Humanos , Japão , Estados Unidos , United States Food and Drug AdministrationRESUMO
Truly disruptive medicine innovation and new treatment paradigms tend to start in non-commercial research institutions. However, the lack of mutual understanding between medicine developers and regulators when it comes to medicine development significantly delays or even prevents the access of patients to these innovations. Here, we outline what regulatory-related barriers hamper the translational development of novel products or new treatment paradigms initiated in academia, and propose key steps towards improved regulatory dialogue among academia, funding bodies and regulatory authorities. Moreover, we briefly describe how the STARS (Strengthening Training of Academia in Regulatory Science) project aims to reach out to medicine innovators in academia to bridge the regulatory knowledge gap and enhance this dialogue to facilitate the implementation of academic research findings in clinical practice.
Assuntos
Difusão de Inovações , Pesquisa Translacional Biomédica/organização & administração , Tecnologia Disruptiva/legislação & jurisprudência , União Europeia , Humanos , Pesquisa Translacional Biomédica/legislação & jurisprudênciaRESUMO
mHealth, the use of mobile and wireless technologies in healthcare, and mHealth apps, a subgroup of mHealth, are expected to result in more person-focussed healthcare. These technologies are predicted to make patients more motivated in their own healthcare, reducing the need for intensive medical intervention. Thus, mHealth app technology might lead to a redesign of existing healthcare architecture making the system more efficient, sustainable, and less expensive. As a disruptive innovation, it might destabilise the existing healthcare organisation through a changed role for healthcare professionals with patients accessing care remotely or online. This account coincides with the broader narrative of National Health Service policy-makers, which focusses on personalised healthcare and greater patient responsibility with the potential for significant cost reductions. The article proposes that while the concept of mHealth apps as a disruptive technology and the narrative of personalisation and responsibilisation might support a transformation of the healthcare system and a reduction of costs, both are dependent on patient trust in the safety and security of the new technology. Forcing trust in this field may only be achieved with the application of traditional and other regulatory mechanisms and with this comes the risk of reducing the effect of the technology's disruptive potential.